Users have described an instant calming effect from a wrist-worn device developed by the University of Nottingham, while a clinical trial found an average 25% reduction in tic frequency as participants used a prototype. The Neupulse device delivers electrical pulses to the median nerve. Its consumer wellness version is on sale, while its medical version, intended to treat tics and Tourette's syndrome, has not yet received regulatory approval; if approval is obtained, it is hoped the device will be considered for NHS use.
The device was developed by the University of Nottingham and its spin-out company Neurotherapuetics Ltd, which secured £1 million in additional funding to commercialise it. The university says thousands of devices have been sold so far. The medical version, Neupulse-M, is intended for the treatment of tics and Tourette's syndrome but has not yet received regulatory approval for this purpose.
Tourette's syndrome is a neurodevelopmental condition with symptoms that usually start in childhood. According to Tourettes Action, more than 300,000 people in the UK have the condition, which is incurable. The Neupulse device delivers electrical pulses to the median nerve at the wrist, which trials have shown can change activity in parts of the brain involved in movement control.
The 2023 clinical trial of 121 people in the UK found an average reduction in tic frequency of 25% while using a prototype of the device. That year, singer Lewis Capaldi, who has Tourette's, also tested the device before a gig in Nottingham; the university said he was impressed by its effects. Tourettes Action said the National Institute for Health and Care Excellence (NICE) had identified the technology as 'promising' and requested further evidence of long-term benefits before making recommendations over NHS adoption.
Among the first to try the device was 15-year-old Katie from Hertfordshire. She first experienced Tourette's symptoms at age seven, describing them as constant. After turning on the device for the first time, she said the effect was 'instant' and called it 'absolutely life-changing'. Her mother, Julia, said it was 'heartbreaking' to see her daughter struggle and that reading about the device made her feel hopeful for her daughter.
Ollie, 15, from Cheshire, began having involuntary neck movements nearly two years ago and was later diagnosed with Functional Neurological Disorder (FND), a neurological condition that affects how the brain and nervous system work. He said the device worked 'like a light switch', adding: 'It's like getting part of your life back.' His father, Alex, said it was 'life-changing'. Mylo, 17, who participated in the trial, said the device made him feel 'new almost' and that it would make 'such a big difference'.
Emma McNally, CEO of Tourettes Action, said users she had spoken to had given the device 'nothing but praise', with some saying it helped them go to places they had not been for a long time, such as the cinema or library. Professor Stephen Jackson, who led the research, said seeing the impact on users had been 'a dream come true' and hoped the device could be available on the NHS 'in the next year or so'.
The university is also exploring the device for other conditions. It has recently been tested in early trials for people with Parkinson's to see if it can be used to reduce tremors, and Professor Jackson said the university was looking to launch a UK-wide clinical trial to look at anxiety and obsessive-compulsive disorder.
Analysis
Why This Matters
- The Neupulse device offers a non-drug, wearable intervention that can reduce tic frequency and intensity, potentially improving daily life for people with Tourette's syndrome.
- If regulatory approval is granted, the device could be made available on the NHS, making it accessible to a large patient population in the UK.
- The technology is being investigated for other neurological conditions such as Parkinson's disease, OCD, and anxiety, broadening its potential impact.
Background
Tourette's syndrome is a neurodevelopmental condition characterised by involuntary sounds and movements (tics), typically starting in childhood. According to Tourettes Action, more than 300,000 people in the UK have the condition, which is incurable. The Neupulse device was developed by the University of Nottingham and its spin-out company Neurotherapeutics Ltd. A 2023 clinical trial of 121 people found an average 25% reduction in tic frequency while using a prototype. NICE has called the technology 'promising' but requested further evidence of long-term benefits before recommending it for NHS adoption.
Key Perspectives
What to Watch
- Regulatory approval decision for Neupulse-M, which Professor Jackson hopes will come within the next year.
- NICE guidance update after further long-term evidence is submitted and evaluated.
- Expansion of clinical trials into anxiety, OCD, and Parkinson's disease, which could open up new uses for the device.
Checked
12 claims in this story checked against 1 source: 10 supported.
Show each claim
- Partly supportedThe Neupulse wrist device reduces Tourette’s tics in a trial and awaits regulatory approval.BBC News: “Neupulse-C - which is available as a consumer wellness device - and Neupulse-M, which is intended to be marketed as a medical device specifically for the treatment of tics and Tourette's syndrome, but it has not yet received regulatory approval for this purpose.”
- Partly supportedUsers have described an instant calming effect from the device.BBC News: “Katie said when she turned it on for the first time, the effect was "instant" and she became "really calm".”
- SupportedA clinical trial found an average 25% reduction in tic frequency while participants used a prototype.BBC News: “In 2023, a clinical trial of 121 people in the UK found they experienced, on average, a reduction in tic frequency of 25% while using a prototype of the device.”
- SupportedThe medical version has not yet received regulatory approval for treating tics and Tourette’s syndrome.BBC News: “Neupulse-M, which is intended to be marketed as a medical device specifically for the treatment of tics and Tourette's syndrome, but it has not yet received regulatory approval for this purpose.”
- SupportedKatie said the effect was “instant”.BBC News: “Katie said when she turned it on for the first time, the effect was "instant" and she became "really calm".”
- SupportedOllie said the device was “like a light switch”.BBC News: “Ollie said: "It's like a light switch. I remember my hands were quite shaky when I was calling my parents because it's like getting part of your life back."”
- SupportedThe clinical trial involved 121 people in the UK.BBC News: “In 2023, a clinical trial of 121 people in the UK found they experienced, on average, a reduction in tic frequency of 25% while using a prototype of the device.”
- SupportedNeurotherapuetics Ltd secured £1 million in additional funding to commercialise the device.BBC News: “The device was developed by the university and its spin-out company Neurotherapuetics Ltd, which secured £1m in additional funding to commercialise the device.”
- SupportedMore than 300,000 people in the UK have Tourette’s syndrome, and the condition is incurable.BBC News: “According to Tourettes Action, more than 300,000 people in the UK have the condition, which is incurable.”
- SupportedTourettes Action said NICE identified the technology as promising and requested further evidence before making recommendations on NHS adoption.BBC News: “The charity added the National Institute for Health and Care Excellence (NICE) had identified the technology as "promising", and had requested further evidence of its long-term benefits before making recommendations over NHS adoption.”
- SupportedMylo said he felt “new almost” and that the device would make “such a big difference”.BBC News: “"I feel different... I feel new almost, which is strange. It's going to be such a big difference."”
- SupportedProfessor Stephen Jackson hoped the device could be available on the NHS “in the next year or so”.BBC News: “Prof Stephen Jackson, who has led the research, said seeing the impact on users of the device had been "a dream come true", and hoped it would be available on the NHS "in the next year or so".”